Pharmaceutical launches sales (annual)

My first months as CEO have focused on assessing the challenges facing Sanofi and working on an accelerated transformation roadmap that leverages our commercial strengths and focuses on the need for R&D and pipeline improvements. We have taken the first decisive steps on pipeline prioritisation and recently, we appointed a focused Executive Committee aligned with the strategic priorities. Looking ahead, we're confident in our trajectory of profitable growth: Dupixent sales are now expected to reach around €25 billion in 2030, complemented by approximately €10 billion from Pharma launches — both at constant exchange rates. This strong financial foundation is expected to support continued pipeline enhancement and external growth opportunities in the years ahead. We are committed to acting and reporting on our progress to shareholders and other stakeholders in the quarters to come.

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA

Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFM

Copy

MLA

Sanofi. "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded." 2026, https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFM.

Copy

Chicago

Sanofi. "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded." 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFM.

Copy

BibTeX

@misc{sanofi2026pharmaceuticalbjmgfm, author = {{Sanofi}}, title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFM}, note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.} }

Copy

Everything needed to check this number yourself, without taking our word for it.

Record last modified 15 September 2026. Value type: forecast. Update cadence: annual. This page is permanently addressable at statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFM.